Haisco(SZ:002653) Bei Jing Shang Bao·2025-04-14 02:32Core Viewpoint - The company reported a revenue of 3.721 billion yuan for 2024, marking a year-on-year increase of 10.92%, while net profit attributable to shareholders reached 395 million yuan, up 34% [1] Group 1: Financial Performance - The company's revenue for 2024 was 3.721 billion yuan, reflecting a 10.92% increase compared to the previous year [1] - Net profit attributable to shareholders was 395 million yuan, representing a 34% year-on-year growth [1] - The company's non-recurring net profit decreased by 45.4% to 132 million yuan, with a loss reported in the fourth quarter [1] Group 2: Factors Affecting Performance - The decline in non-recurring net profit was primarily due to increased investment in innovative drug research and development, with R&D expenses amounting to 62.414 million yuan, an increase of 10.746 million yuan year-on-year [1] - Asset impairment losses for the year totaled 82.39 million yuan, up 7.226 million yuan from the previous year, mainly due to a 53.45 million yuan impairment loss from the termination of the riluzole project [1] - In the fourth quarter, R&D expenses were particularly high at 24.616 million yuan, accounting for approximately 39% of the annual R&D expenses [1] Group 3: Government Support and Market Reaction - The company received significant government subsidies amounting to 189 million yuan, linked to local policy execution [2] - On April 11, the company's stock price hit a historical high, closing at a limit-up, but subsequently experienced a decline of over 5% on April 14 [2] - As of the latest report, the stock price was 45.82 yuan per share, reflecting a decrease of 3.44% [2]